HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIAL
The study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2011-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839577013703147520 |
|---|---|
| author | M. V. Reshetnyak V. N. Khirmanov N. N. Zybina M. Yu. Frolova |
| author_facet | M. V. Reshetnyak V. N. Khirmanov N. N. Zybina M. Yu. Frolova |
| author_sort | M. V. Reshetnyak |
| collection | DOAJ |
| description | The study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered 6-day “test” acarbose therapy. At baseline and 7 days later, saccharose tolerance test was performed, with the measurement of venous plasma levels of fasting UA, fasting fructose, glucose (fasting, 60 and 120 minutes after saccharose load), and insulin (fasting and 120 minutes after the load). 4 weeks later, 20 patients were administered 8-week acarbose therapy, with standard gradual dose increase. At baseline and after the treatment, venous plasma concentrations of UA and fructose were measured. Results. Hyperfructosemia was observed in 100% of the patients, with mean plasma fructose concentration of 0,82±0,97 mmol/l. Hyperuricemia was observed in 51,5% (n=17), with mean plasma UA concentration of 413,2±86,5 mmol/l. Six-week acarbose therapy resulted in a significant decrease of UA levels (p=0,0015) and fructose levels (p=0,049), as well as in postprandial levels of glucose (p=0,03) and insulin (p=0,013). Eight-week acarbose therapy was associated with mean decrease of plasma UA concentration by 5,8% (p=0,04), but no significant changes in fasting plasma levels of fructose (p>0,05). |
| format | Article |
| id | doaj-art-1ae985e7fc9e4516b08a880e1e63c0a0 |
| institution | Matheson Library |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2011-04-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-1ae985e7fc9e4516b08a880e1e63c0a02025-08-04T13:00:05Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202011-04-01025458953HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIALM. V. Reshetnyak0V. N. Khirmanov1N. N. Zybina2M. Yu. Frolova3Всероссийский центр экстренной и радиационной медицины им. А. М. Никифорова МЧС России, Санкт-ПетербургВсероссийский центр экстренной и радиационной медицины им. А. М. Никифорова МЧС России, Санкт-ПетербургВсероссийский центр экстренной и радиационной медицины им. А. М. Никифорова МЧС России, Санкт-ПетербургВсероссийский центр экстренной и радиационной медицины им. А. М. Никифорова МЧС России, Санкт-ПетербургThe study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered 6-day “test” acarbose therapy. At baseline and 7 days later, saccharose tolerance test was performed, with the measurement of venous plasma levels of fasting UA, fasting fructose, glucose (fasting, 60 and 120 minutes after saccharose load), and insulin (fasting and 120 minutes after the load). 4 weeks later, 20 patients were administered 8-week acarbose therapy, with standard gradual dose increase. At baseline and after the treatment, venous plasma concentrations of UA and fructose were measured. Results. Hyperfructosemia was observed in 100% of the patients, with mean plasma fructose concentration of 0,82±0,97 mmol/l. Hyperuricemia was observed in 51,5% (n=17), with mean plasma UA concentration of 413,2±86,5 mmol/l. Six-week acarbose therapy resulted in a significant decrease of UA levels (p=0,0015) and fructose levels (p=0,049), as well as in postprandial levels of glucose (p=0,03) and insulin (p=0,013). Eight-week acarbose therapy was associated with mean decrease of plasma UA concentration by 5,8% (p=0,04), but no significant changes in fasting plasma levels of fructose (p>0,05).https://russjcardiol.elpub.ru/jour/article/view/1149hyperuricemiafructosemetabolic syndromeimpaired glucose tolerancediabetes mellitusacarbose |
| spellingShingle | M. V. Reshetnyak V. N. Khirmanov N. N. Zybina M. Yu. Frolova HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIAL Российский кардиологический журнал hyperuricemia fructose metabolic syndrome impaired glucose tolerance diabetes mellitus acarbose |
| title | HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIAL |
| title_full | HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIAL |
| title_fullStr | HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIAL |
| title_full_unstemmed | HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIAL |
| title_short | HYPERURICEMIA CORRECTION IN MEN WITH METABOLIC SYNDROME: ACARBOSE POTENTIAL |
| title_sort | hyperuricemia correction in men with metabolic syndrome acarbose potential |
| topic | hyperuricemia fructose metabolic syndrome impaired glucose tolerance diabetes mellitus acarbose |
| url | https://russjcardiol.elpub.ru/jour/article/view/1149 |
| work_keys_str_mv | AT mvreshetnyak hyperuricemiacorrectioninmenwithmetabolicsyndromeacarbosepotential AT vnkhirmanov hyperuricemiacorrectioninmenwithmetabolicsyndromeacarbosepotential AT nnzybina hyperuricemiacorrectioninmenwithmetabolicsyndromeacarbosepotential AT myufrolova hyperuricemiacorrectioninmenwithmetabolicsyndromeacarbosepotential |